Sona Nanotech Inc C.SONA

Alternate Symbol(s): SNANF

Technology Scientific & Technical Instruments

Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.

CSE:SONA - Post by User

Sona Nanotech Inc

<< Previous

Bullboard Posts

Next >>

Post by Dillygafon Aug 20, 2020 12:08pm

141 Views

Post# 31434029

NR says 1 more week

Which is on par with August 14th NR. No surprises here.

Vancouver, BC – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (“Sona Nanotech” or the “Company”), a developer of rapid, point-of-care diagnostic tests, announces that it expects to release a report on its clinical, in-field evaluation studies for its rapid detection, COVID-19 antigen test next week. This data will be used to support the Company's submissions to Health Canada and the FDA for emergency use authorization ("EUA") approval for its COVID-19 antigen test.

The Company is reliant on third parties and testing protocols with multiple complex variables, many of which are outside of the control of the Company and can impact expected timing of results.